Skip to content
SPACListing
Completed1 extension

Intelligent Medicine Acquisition Corp.

CIK 0001850051

Cash in trust

$214M

$213,846,754

Trust per share

$10.33

Redemption value

IPO

Nov 2021

$203M raised

Combination deadline

—

Not disclosed

Filings on record

63

Latest Feb 14, 2024

Business combination

Target
Not disclosed in an indexed filing
Announced
Feb 22, 2023
Closed
May 12, 2023

Overview

Intelligent Medicine Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001850051. It completed its initial public offering in Nov 2021, raising $203M in gross proceeds. The vehicle is sponsored by Intelligent Medicine through Intelligent Medicine Sponsor LLC. The mandate targets technology, healthcare, education. Business combination closed; the company trades under a new ticker.

“we intend to focus our search on life science companies that are using artificial intelligence (“AI”), machine learning (“ML”) and big data to create and power a new model of drug discovery through research and development that is far faster, less expensive and more predictable than the decades-old system of drug development we still follow today.”
The mandate, as stated in the IPO prospectus

Reading the filings

Arithmetic on what Intelligent Medicine Acquisition Corp. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Trust versus the $10 unit

    The trust holds $10.33 per public share, 3.3% above the $10.00 the units were sold at. That spread is accrued interest on the trust and, where the charter provides for it, sponsor contributions paid in to buy more time. It is the floor a public shareholder can redeem at, not a valuation of the business.

  • Extension history

    Shareholders have already approved 1 extension. Each one opened a redemption window, so the public float and the trust are almost certainly smaller than at IPO, and each typically came with a sponsor contribution that lifts trust per share. A vehicle on its second or third extension is one where the sponsor is paying to keep the search alive.

  • Warrant coverage

    Each unit carried one-half warrant per unit. Warrants are dilution deferred: they cost the holder nothing until exercised, and they overhang the post-combination share count. Thinner coverage is generally a sign of a stronger book at pricing.

  • Underwriting

    Cantor Fitzgerald led the offering. It has been named on 151 SPAC IPOs, book-running 130 of them, and 69.5% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.

How busy it has been

Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.

18902021-032024-02

63 filings in all. 1 in the last three months, against a busiest month of 18.

News on Intelligent Medicine Acquisition Corp.

Last 90 days

Nothing in the last 90 days that names this vehicle. We attribute a story only when the release carries the ticker or the registered name, so an empty section means no press release or wire story matched — not that nothing was published. The filings below are the primary record either way.

SEC filing history

Free tier: filings older than 24 hours
  • SC 13G

    Beneficial ownership report (passive)

    Accession 0001104659-24-022617

    Feb 14, 2024

    2y ago

    View on EDGAR ↗
  • 15-12G

    Deregistration of securities

    Accession 0001104659-23-059809

    May 12, 2023

    3y ago

    View on EDGAR ↗
  • 25-NSE

    Notification of delisting

    Accession 0001354457-23-000333

    May 2, 2023

    3y ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001209191-23-025910

    Apr 27, 2023

    3y ago

    View on EDGAR ↗
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001104659-23-049966

    Apr 26, 2023

    3y ago

    View on EDGAR ↗
  • 10-K

    Annual report

    Accession 0001104659-23-046201

    Apr 17, 2023

    3y ago

    View on EDGAR ↗
  • SC 13G/A

    FORM SC 13G/A

    Accession 0001062993-23-009089

    Apr 13, 2023

    3y ago

    View on EDGAR ↗
  • 8-K

    Notice of delisting or failure to satisfy a listing rule

    Items 3.01, 9.01 · Accession 0001104659-23-043149

    Apr 7, 2023

    3y ago

    View on EDGAR ↗
  • 8-K

    Notice of delisting or failure to satisfy a listing rule

    Item 3.01 · Accession 0001104659-23-042169

    Apr 5, 2023

    3y ago

    View on EDGAR ↗
  • NT 10-K

    Late annual report notification

    Accession 0001104659-23-040748

    Apr 3, 2023

    3y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001510281-23-000025

    Feb 28, 2023

    3y ago

    View on EDGAR ↗
  • 425

    Business-combination communication

    Accession 0001104659-23-024379

    Feb 22, 2023

    3y ago

    View on EDGAR ↗
  • 8-K

    Entry into a material definitive agreement

    Items 1.01, 2.03, 9.01 · Accession 0001104659-23-024376

    Feb 22, 2023

    3y ago

    View on EDGAR ↗
  • SC 13D

    Beneficial ownership report (activist)

    Accession 0001104659-23-023806

    Feb 21, 2023

    3y ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001104659-23-018561

    Feb 10, 2023

    3y ago

    View on EDGAR ↗
  • 8-K

    Submission of matters to a vote of security holders

    Items 5.03, 5.07, 9.01 · Accession 0001104659-23-017381

    Feb 9, 2023

    3y ago

    View on EDGAR ↗
  • DEFA14A

    Additional proxy soliciting material

    Accession 0001104659-23-010625

    Feb 3, 2023

    3y ago

    View on EDGAR ↗
  • 8-K

    Regulation FD disclosure

    Items 7.01, 9.01 · Accession 0001104659-23-010616

    Feb 3, 2023

    3y ago

    View on EDGAR ↗
  • DEFA14A

    Additional proxy soliciting material

    Accession 0001104659-23-007268

    Jan 27, 2023

    3y ago

    View on EDGAR ↗
  • DEF 14A

    Definitive proxy statement

    Accession 0001104659-23-005025

    Jan 19, 2023

    3y ago

    View on EDGAR ↗
  • UPLOAD

    SEC staff comment letter

    Accession 0000000000-23-000533

    Jan 18, 2023

    3y ago

    View on EDGAR ↗
  • CORRESP

    Correspondence with SEC staff

    Accession 0001104659-23-004227

    Jan 17, 2023

    3y ago

    View on EDGAR ↗
  • UPLOAD

    SEC staff comment letter

    Accession 0000000000-23-000425

    Jan 17, 2023

    3y ago

    View on EDGAR ↗
  • PRE 14A

    PRE 14A

    Accession 0001104659-23-000869

    Jan 4, 2023

    3y ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001104659-22-118572

    Nov 14, 2022

    3y ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001104659-22-091384

    Aug 15, 2022

    4y ago

    View on EDGAR ↗
  • 3/A

    PRIMARY DOCUMENT

    Accession 0001510281-22-000121

    Jun 7, 2022

    4y ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001104659-22-062088

    May 17, 2022

    4y ago

    View on EDGAR ↗
  • NT 10-Q

    Late quarterly report notification

    Accession 0001104659-22-061829

    May 17, 2022

    4y ago

    View on EDGAR ↗
  • SC 13G/A

    FORM SC 13G/A

    Accession 0001062993-22-011872

    May 9, 2022

    4y ago

    View on EDGAR ↗

Pro

Track Intelligent Medicine Acquisition Corp. without the delay

Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.

  • Filings live, no 24-hour delay
  • One click through to the source document
  • Deadline calendar out to 12 months
  • CSV export, API and MCP access

Cancel any time. Billed monthly in USD.

Intelligent Medicine Acquisition Corp.: questions answered

What is Intelligent Medicine Acquisition Corp.?

Intelligent Medicine Acquisition Corp. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001850051. It completed its initial public offering in Nov 2021, raising $203M in gross proceeds. The vehicle is sponsored by Intelligent Medicine through Intelligent Medicine Sponsor LLC. The mandate targets technology, healthcare, education. Business combination closed; the company trades under a new ticker.

How much does Intelligent Medicine Acquisition Corp. hold in trust?

Approximately $213,846,754, or about $10.33 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must Intelligent Medicine Acquisition Corp. complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if Intelligent Medicine Acquisition Corp. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Intelligent Medicine Acquisition Corp., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.33 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

Is the trust value the same as the share price for Intelligent Medicine Acquisition Corp.?

No. Trust per share is a disclosed, contractual figure: what a redeeming holder receives. The market price is whatever the shares change hands at, which can sit above the trust when a deal is well received or below it when the market doubts one will close. We do not have a current quote for this vehicle, so no spread is shown.

How much dilution do Intelligent Medicine Acquisition Corp.'s founder shares and warrants create?

Each unit also carried one-half warrant per unit, which is dilution deferred until exercise. Both are disclosed in the prospectus and both survive into the combined company, which is why a de-SPAC at $10 is not economically the same as an IPO at $10.

Who sponsors Intelligent Medicine Acquisition Corp., and what is their track record?

Intelligent Medicine Sponsor LLC is the sponsor entity, part of the Intelligent Medicine franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Gregory C. Simon.

Which banks underwrote the Intelligent Medicine Acquisition Corp. IPO?

Cantor Fitzgerald. Syndicate membership and role are read from the prospectus cover and the underwriting section.

Is Intelligent Medicine Acquisition Corp. a good investment?

That is not a question this site answers. Intelligent Medicine Acquisition Corp. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Intelligent Medicine Acquisition Corp. data come from?

Filings Intelligent Medicine Acquisition Corp. submitted to the SEC under CIK 0001850051: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Oct 19, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.